17 articles, transcripts, and reports
The market has been closely following the activities of leading biopharma companies for some time, looking for updates on their COVID vaccine programs. With most…
After Novavax (NASDAQ: NVAX) reported its progress on developing the COVID-19 vaccine at the end of February, the shares of the company started trading in…
Novavax Inc (NASDAQ: NVAX) Q2 2020 earnings call dated Aug. 10, 2020 Corporate Participants: Silvia Taylor — Senior Vice President, Investor Relations and Corporate Affairs Stanley C.…
Novavax (NASDAQ: NVAX) reported a loss of $17.5 million or $0.30 per share for the second quarter of 2020. Revenue jumped to $35.54 million in…
For Novavax Inc. (NASDAQ: NVAX), the new fiscal year is of great significance due to the progress it has achieved in developing Covid-19 vaccine. At…
Novavax Inc. (NVAX) Q1 2020 earnings call dated May 11, 2020 Corporate Participants: Erika Trahan — Investor Relations Stanley C. Erck — President and Chief Executive Officer John J.…
Novavax Inc. (NASDAQ: NVAX) reported a narrower loss for the fourth quarter of 2019 helped by higher revenue and lower expenses. The bottom line was…
